# Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic Encephalitis

> **NCT00000794** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 100 (—)

## Conditions studied

- Toxoplasmosis, Cerebral
- HIV Infections

## Interventions

- **DRUG:** Sulfadiazine
- **DRUG:** Clarithromycin
- **DRUG:** Atovaquone
- **DRUG:** Pyrimethamine
- **DRUG:** Leucovorin calcium

## Key facts

- **NCT ID:** NCT00000794
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 1998-04
- **Target enrollment:** 100 (—)
- **Last updated:** 2021-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00000794

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00000794, "Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic Encephalitis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00000794. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*